RxDoctor Payments DataLook up a doctor →

Fabian Lugo, MD

Neurology · Lafayette, LANPI 1538190798

Payments from drug & device makers

$26,517in general payments, 2019–2025

Across 1,467 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Neurocrine Biosciences, Inc.$2K
  • UCB, Inc.$2K
  • Acadia Pharmaceuticals Inc$2K
  • Biogen$1K
  • Eisai Inc.$1K
  • plus $14K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)221$3,716
Neurocrine Biosciences, Inc.119$2,289
UCB, Inc.74$1,870
Acadia Pharmaceuticals Inc117$1,631
Biogen88$1,412
Eisai Inc.59$1,210
SK Life Science, Inc.58$1,099
AstraZeneca(2 entities)34$996
Lundbeck LLC64$941
Sunovion Pharmaceuticals Inc.70$864
Teva Pharmaceuticals USA, Inc.47$862
Amneal Pharmaceuticals LLC65$858
Amgen(2 entities)34$824
Lilly USA, LLC42$729
Argenx US, Inc.26$678
Pfizer36$610
MDD US Operations, LLC25$545
Novartis24$501
Kyowa Kirin, Inc.26$424
Bristol Myers Squibb25$383
Axsome Therapeutics, Inc.3$260
Avanir Pharmaceuticals, Inc.14$248
Adamas Pharmaceuticals, Inc.16$236
Otsuka America Pharmaceutical, Inc.11$224
Neurelis, Inc.10$223
Impel Pharmaceuticals Inc.13$198
GE HealthCare11$197
Johnson & Johnson(2 entities)7$195
E.r. Squibb & Sons, L.L.C.6$179
Supernus Pharmaceuticals, Inc.13$167
CSL Behring7$156
EMD Serono, Inc.10$153
Biohaven Pharmaceuticals, Inc.10$149
Takeda Pharmaceuticals U.S.A., Inc.8$149
Genentech USA, Inc.5$148
Sumitomo Pharma America, Inc.11$142
Biohaven Pharmaceutical Holding Company Ltd.9$127
Jazz Pharmaceuticals Inc.7$123
TG Therapeutics, Inc.4$101
Arbor Pharmaceuticals, Inc.6$87
Sanofi5$86
Aucta Pharmaceuticals, Inc.3$80
Greenwich Biosciences, Inc.1$69
Mallinckrodt Hospital Products Inc.4$67
Upsher-smith Laboratories LLC3$47
Grifols USA, LLC2$40
Tanabe Pharma America, Inc.2$33
ANI Pharmaceuticals, Inc.2$32
Vanda Pharmaceuticals Inc.2$29
Merz Pharmaceuticals, LLC1$26
Cycle Pharmaceuticals Inc1$23
Insightec,inc1$18
Acorda Therapeutics, Inc1$15
Catalyst Pharmaceuticals, Inc.1$14
Idorsia Pharmaceuticals US Inc1$13
Promius Pharma LLC1$13
Zyla Life Sciences, Inc.1$12

How this compares

$26,517 in reported general payments places this provider in the 85th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$126,613
Medicare patients
546
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →